Winfried J. Randerath Germany

After his medical studies in 1987 at the University of Duesseldorf in Germany, Dr Randerath has entered the field of pneumology with a focus on respiratory and sleep medicine. He holds the position as Medical Director at the Bethanien Hospital, Solingen, Germany, Clinic for Pneumology and Allergology, Center for Sleep Medicine and Respiratory Care as well as the position Director of the Institute of Pneumology at the University of Cologne. He is board certified in Internal Medicine, Pulmonary Disease, Allergology, Environmental Medicine, Palliative Medicine and Sleep Medicine. He published over 300 hundred national and international papers and is Editor in Chief of Sleep Medicine and Sleep Medicine X as well as Karger Kompass Pneumologie and Associate Editor of Respiration and ERJ open Research. He is a Fellow of the American Thoracic Society, the American Association of Sleep Medicine and the American College of Chest Physicians and was awarded the Teaching Award of the European Respiratory Society and the Meier-Ewert-Price of the German Dental Sleep Medicine Society. He was Secretary General of the German Respiratory Society from 2018 - 2024 and has served as a board member of the German Society for Sleep Research and Sleep Medicine as well as Chair of the Northern Westphalian Society of Sleep Medicine from 2009 to 2020. Within ERS he is Guidelines Director for the period 2024 - 2027. He served as Assembly Head of Assembly 4, Sleep Disordered Breathing from 2021 to 2023. Before, he has served as Group Chair of group 4.02 Sleep and Control of Breathing from 2015–2018. He is a member of the ERS Adult Examination Committee since 2019 and served as a member of the ERS Guidelines Committee from 2018 – 2021. He chaired multiple ERS Task Forces: CPAP therapies (started 2022),Technical Standards (Statement finished 2022) non-CPAP therapies (Guideline finished 2021), Sleep and Stroke (Statement finished 2019), Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep (Statement finished 2016), non-CPAP therapies (Statement finished 2011) HERMES (finished 2014). Dr Randerath chaired the congress of the German Respiratory Society in 2018, the congress of the German Society for Sleep Research and Sleep Medicine in 2007 and 2014. His main research activities are: differentiation of obstructive and central sleep apnoea, interaction of sleep apnoea and the heart, pulmonary intensive care, chronic respiratory failure.
Job Title
Director, Institute for Pulmonology
Faculty / Department / Division
Pneumology
Institution / Organisation
University of Cologne

19 November 2026, Thursday

Time Session
08:30
13:00
Naricha Chirakalwasan Chairperson Thailand
Rashidah Yasin Chairperson Malaysia
Function Room 8, Ground Mezzanine Floor

21 November 2026, Saturday

Time Session
11:00
12:30
Allen Widysanto Chairperson Indonesia
Rashidah Yasin Chairperson Malaysia
  • Naricha Chirakalwasan Speaker Thailand
  • Kah-Lin Choo Speaker Singapore
    Toward Personalised Non-PAP Therapy for Obstructive Sleep Apnoea While positive airway pressure (PAP) remains the gold standard treatment for obstructive sleep apnoea (OSA), long-term compliance is frequently limited by patient intolerance. Emerging insights into the pathophysiology of OSA reveal that the condition is not solely driven by anatomical airway collapse; rather, it is governed by four distinct endotypes that include three non-anatomical endotypes such as poor upper airway muscle responsiveness, low respiratory arousal threshold, and high loop gain (ventilatory control instability). This paradigm shift paves the way for precision medicine and targeted, non-PAP therapeutic strategies tailored to individual physiological profiles. This lecture will review recent advances in non-PAP therapeutic modalities mapped to specific OSA endotypes, examine clinical trial evidence, and address current challenges and future directions in clinical phenotyping and personalized care. Strategies include anti-obesity interventions such as dual GIP/GLP-1 receptor agonists and structural stabilization through hypoglossal or ansa cervicalis nerve stimulation, pharmacological neuromuscular stabilization, loop gain modulation and arousal threshold management. Personalising non-PAP therapy based on individual pathophysiological traits offers a promising paradigm for patients who refuse or are intolerant to PAP. Future clinical success relies on validating automated computational phenotyping tools within routine diagnostic workflows, standardizing prediction thresholds across diverse global populations, and establishing outcome-focused trials linked to hard clinical endpoint.
  • Winfried J. Randerath Speaker Germany
  • Q&A
Ballroom 2, Lower Ground Floor